Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCLI NASDAQ:BTAI NASDAQ:KPRX NASDAQ:SLRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCLIBrainstorm Cell Therapeutics$0.84$1.17$0.59▼$6.00$8.27M0.22701,690 shs70,341 shsBTAIBioXcel Therapeutics$1.94+1.3%$1.68$1.17▼$19.84$11.45M0.041.23 million shs26,856 shsKPRXKiora Pharmaceuticals$3.16-0.6%$3.07$2.51▼$4.86$9.61M-0.66222,222 shs7,119 shsSLRXSalarius Pharmaceuticals$0.63+2.8%$0.83$0.45▼$7.20$1.35M0.441.46 million shs10,067 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCLIBrainstorm Cell Therapeutics0.00%-28.75%-29.92%-0.58%-83.54%BTAIBioXcel Therapeutics0.00%-3.05%+19.38%+11.70%-89.80%KPRXKiora Pharmaceuticals0.00%+6.00%-0.63%+10.80%-29.33%SLRXSalarius Pharmaceuticals0.00%-17.81%-46.54%-10.91%-66.40%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCLIBrainstorm Cell Therapeutics1.1675 of 5 stars0.02.00.04.71.60.80.6BTAIBioXcel Therapeutics3.6962 of 5 stars3.32.00.04.50.61.70.6KPRXKiora Pharmaceuticals3.2526 of 5 stars3.55.00.00.02.21.70.6SLRXSalarius Pharmaceuticals0.2499 of 5 stars0.02.00.00.01.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCLIBrainstorm Cell Therapeutics 0.00N/AN/AN/ABTAIBioXcel Therapeutics 2.67Moderate Buy$42.602,101.55% UpsideKPRXKiora Pharmaceuticals 3.00Buy$10.00216.46% UpsideSLRXSalarius Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($1.36) per shareN/ABTAIBioXcel Therapeutics$2.27M5.17N/AN/A($30.01) per share-0.06KPRXKiora Pharmaceuticals$16.02M0.60$1.23 per share2.57$8.58 per share0.37SLRXSalarius PharmaceuticalsN/AN/AN/AN/A$0.95 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCLIBrainstorm Cell Therapeutics-$11.62M-$3.36N/AN/AN/AN/AN/A-519.50%8/13/2025 (Estimated)BTAIBioXcel Therapeutics-$59.60M-$13.55N/AN/AN/A-2,163.18%N/A-83.80%8/5/2025 (Estimated)KPRXKiora Pharmaceuticals$3.60M-$2.90N/AN/AN/AN/A-42.82%-32.18%8/8/2025 (Estimated)SLRXSalarius Pharmaceuticals-$5.58M-$4.82N/A∞N/AN/A-324.13%-174.40%8/8/2025 (Estimated)Latest SLRX, KPRX, BTAI, and BCLI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025BCLIBrainstorm Cell Therapeutics-$0.41N/AN/AN/AN/AN/A8/8/2025Q2 2025KPRXKiora Pharmaceuticals-$0.58N/AN/AN/A$0.75 millionN/A8/5/2025Q2 2025BTAIBioXcel Therapeutics-$2.30N/AN/AN/A$0.21 millionN/A5/15/2025Q1 2025BCLIBrainstorm Cell Therapeutics-$0.38-$0.45-$0.07-$0.45N/AN/A5/14/2025Q1 2025SLRXSalarius Pharmaceuticals-$2.40-$1.03+$1.37-$1.03N/AN/A5/12/2025Q1 2025BTAIBioXcel Therapeutics-$2.72-$1.50+$1.22-$1.50$0.35 million$0.17 million5/9/2025Q1 2025KPRXKiora Pharmaceuticals-$0.77-$0.52+$0.25-$0.52$0.75 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/ABTAIBioXcel TherapeuticsN/AN/AN/AN/AN/AKPRXKiora PharmaceuticalsN/AN/AN/AN/AN/ASLRXSalarius PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCLIBrainstorm Cell TherapeuticsN/A0.210.21BTAIBioXcel TherapeuticsN/A1.481.45KPRXKiora PharmaceuticalsN/A5.145.14SLRXSalarius PharmaceuticalsN/A1.011.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCLIBrainstorm Cell Therapeutics14.33%BTAIBioXcel Therapeutics30.68%KPRXKiora Pharmaceuticals76.97%SLRXSalarius Pharmaceuticals11.88%Insider OwnershipCompanyInsider OwnershipBCLIBrainstorm Cell Therapeutics11.15%BTAIBioXcel Therapeutics21.20%KPRXKiora Pharmaceuticals0.05%SLRXSalarius Pharmaceuticals1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCLIBrainstorm Cell Therapeutics409.84 million8.74 millionOptionableBTAIBioXcel Therapeutics906.06 million4.77 millionOptionableKPRXKiora Pharmaceuticals103.04 million3.04 millionNot OptionableSLRXSalarius Pharmaceuticals202.13 million2.10 millionNot OptionableSLRX, KPRX, BTAI, and BCLI HeadlinesRecent News About These CompaniesSalarius Pharmaceuticals (NASDAQ:SLRX) Trading Up 0.1% - Should You Buy?July 16, 2025 | americanbankingnews.comSalarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity StandardJuly 14, 2025 | finance.yahoo.comSalarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity StandardJuly 14, 2025 | globenewswire.comSalarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role ...July 11, 2025 | morningstar.comMSalarius Pharmaceuticals shareholders approve reverse stock split and share issuanceJuly 10, 2025 | uk.investing.comSalarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published StudiesJuly 10, 2025 | finance.yahoo.comSalarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published StudiesJuly 9, 2025 | globenewswire.comSalarius Granted Nasdaq Extension To Regain Compliance With Listing StandardsJune 18, 2025 | nasdaq.comSalarius Pharmaceuticals faces Nasdaq delisting over rule breachesApril 27, 2025 | investing.comSalarius Pharmaceuticals announces Langer to join SABApril 17, 2025 | markets.businessinsider.comSalarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory BoardApril 16, 2025 | globenewswire.comSalarius Pharmaceuticals sees cash runway through later part of 2Q25March 26, 2025 | markets.businessinsider.comSalarius Pharmaceuticals reports FY24 EPS ($5.79) vs. ($30.74) last yearMarch 26, 2025 | markets.businessinsider.comSalarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business UpdateMarch 24, 2025 | finanznachrichten.deSalarius Pharmaceuticals Reports 2024 Financial Results and Provides Business UpdateMarch 24, 2025 | globenewswire.comSalarius resumes trial for MDS and CMML treatmentFebruary 3, 2025 | msn.comSalarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic CancersFebruary 3, 2025 | globenewswire.comSalarius Pharmaceuticals Inc (SLRX) Stock Trading RecapJanuary 17, 2025 | bovnews.comBSalarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger AgreementJanuary 15, 2025 | finanznachrichten.deSalarius Pharmaceuticals Inc (SLRX) Stock: A Deeper Look at Its True PotentialJanuary 14, 2025 | bovnews.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLRX, KPRX, BTAI, and BCLI Company DescriptionsBrainstorm Cell Therapeutics NASDAQ:BCLI$0.84 0.00 (0.00%) As of 09:42 AM EasternBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.BioXcel Therapeutics NASDAQ:BTAI$1.94 +0.03 (+1.31%) As of 09:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.Kiora Pharmaceuticals NASDAQ:KPRX$3.16 -0.02 (-0.63%) As of 09:56 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.Salarius Pharmaceuticals NASDAQ:SLRX$0.63 +0.02 (+3.12%) As of 09:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
